首页> 美国卫生研究院文献>Aging (Albany NY) >SNHG22 overexpression indicates poor prognosis and induces chemotherapy resistance via the miR-2467/Gal-1 signaling pathway in epithelial ovarian carcinoma
【2h】

SNHG22 overexpression indicates poor prognosis and induces chemotherapy resistance via the miR-2467/Gal-1 signaling pathway in epithelial ovarian carcinoma

机译:SNHG22过表达表明上皮性卵巢癌的预后不良并通过miR-2467 / Gal-1信号通路诱导化疗耐药

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Recently, an increasing number of studies have reported that dysregulation of long noncoding RNAs (lncRNAs) plays an important role in cancer initiation and progression, including in epithelial ovarian carcinoma (EOC). However, little is known about the detailed biological functions of the lncRNA small nucleolar RNA host gene 22 (SNHG22) during the progression of EOC. Here, we found that SNHG22 was significantly increased in EOC tissues and was significantly associated with a low level of differentiation. Forced SNHG22 expression promoted chemotherapy resistance in EOC cells. Knockdown of SNHG22 expression increased the sensitivity of EOC cells to cisplatin and paclitaxel. Importantly, we found that SNHG22 could directly interact with miR-2467 and lead to the release of miR-2467-targeted Gal-1 mRNA. Moreover, SNHG22 overexpression induced EOC cell resistance to chemotherapy agents via PI3K/AKT and ERK cascade activation. In summary, our findings demonstrate that SNHG22 plays a critical role in the chemotherapy resistance of EOC by mediating the miR-2467/Gal-1 regulatory axis.
机译:最近,越来越多的研究报告说,长非编码RNA(lncRNA)的失调在癌症的发生和发展中起着重要作用,包括在上皮性卵巢癌(EOC)中。然而,人们对Enc进展过程中lncRNA小核仁RNA宿主基因22(SNHG22)的详细生物学功能了解甚少。在这里,我们发现SNHG22在EOC组织中显着增加,并且与低分化水平显着相关。强迫的SNHG22表达促进EOC细胞的化疗耐药性。抑制SNHG22表达可增加EOC细胞对顺铂和紫杉醇的敏感性。重要的是,我们发现SNHG22可以直接与miR-2467相互作用,并导致靶向miR-2467的Gal-1 mRNA的释放。此外,SNHG22过表达通过PI3K / AKT和ERK级联激活诱导EOC细胞对化疗药物的耐药性。总而言之,我们的发现表明SNHG22通过介导miR-2467 / Gal-1调控轴在EOC的化疗耐药性中起关键作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号